Nazir Ismail

Nazir Ismail

Auto-generated profile, based on publicly available information

Nazir Ismail

Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in EBioMedicine
Verified
Journal Article
Open access
NINazir A. Ismail
Nazir A. Ismail
Shaheed Vally OmarShaheed Vally Omar
Shaheed Vally Omar
LJLavania Joseph
Lavania Joseph
NGNetricia Govender
Netricia Govender
LBLinsay Blows
Linsay Blows
NNNorbert Ndjeka
Norbert Ndjeka
Bedaquiline (BDQ) is a novel agent approved for use in combination treatment of multi-drug resistant tuberculosis (MDR-TB). We sought to determine BDQ epidemiological cut-off values (ECVs), define and assess interpretive criteria against putative resistance associated variants (RAVs), microbiological outcomes and cross resistance with clofazimine (CFZ). A retrospective cohort study was conducted. Minimal inhibitory concentrations (MIC) to BDQ were determined using 7H9 broth microdilution (BMD) and MGIT960. RAVs were genetically characterised using whole genome sequencing. BDQ ECVs were determined using ECOFFinder and compared with 6-month culture conversion status and CFZ MICs. A total of 391 isolates were analysed. Susceptible and intermediate categories were determined to have MICs of ≤0.125μg/ml and 0.25μg/ml using BMD and ≤1μg/ml and 2μg/ml using MGIT960 respectively. Microbiological failures occurred among BDQ exposed patients with a non-susceptible BDQ MIC, an Rv0678 mutation and ≤2 active drug classes. The Rv0678 RAVs were not the dominant mechanism of CFZ resistance and cross resistance was limited to isolates with an Rv0678 mutation. Criteria for BDQ susceptibility are defined and will facilitate improved early detection of resistance. Cross- resistance between BDQ and CFZ is an emerging concern but in this study was primarily among those with an Rv0678 mutation.

21 May 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
JCJeffrey M. Collins
Jeffrey M. Collins
ASAmnah Siddiqa
Amnah Siddiqa
DJDean P. Jones
Dean P. Jones
KLKen Liu
Ken Liu
RKRussell R. Kempker
Russell R. Kempker
TZThomas Ziegler
Thomas Ziegler
There is limited understanding of the role of host metabolism in the pathophysiology of human tuberculosis (TB). Using high-resolution metabolomics with an unbiased approach to metabolic pathway analysis, we discovered that the tryptophan pathway is highly regulated throughout the spectrum of TB infection and disease. This regulation is characterized by increased catabolism of tryptophan to kynurenine, which was evident not only in active TB disease but also in latent TB infection (LTBI). Further, we found that tryptophan catabolism is reversed with effective treatment of both active TB disease and LTBI in a manner commensurate with bacterial clearance. Persons with active TB and LTBI also exhibited increased expression of indoleamine 2,3-dioxygenase-1 ( IDO-1 ), suggesting IDO-1 mediates observed increases in tryptophan catabolism. Together, these data indicate IDO-1–mediated tryptophan catabolism is highly preserved in the human response to Mycobacterium tuberculosis and could be a target for biomarker development as well as host-directed therapies.

21 October 2020 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
SBS. Battaglia
S. Battaglia
ASAndrea Spitaleri
Andrea Spitaleri
ACA. M. Cabibbe
A. M. Cabibbe
CMC. J. Meehan
C. J. Meehan
CUC. Utpatel
C. Utpatel
DCDaniela Cirillo
Daniela Cirillo
The role of mutations in genes associated with phenotypic resistance to bedaquiline (BDQ) and delamanid (DLM) in Mycobacterium tuberculosis complex (MTBc) strains is poorly characterized. A clear understanding of genetic variants9 role is crucial to guide the development of molecular-based drug susceptibility testing (DST). In this work, we analysed all mutations in candidate genomic regions associated with BDQ- and DLM-resistant phenotypes using a whole genome sequencing (WGS) dataset from a collection of 4795 MTBc clinical isolates from six high-burden countries of tuberculosis (TB). From WGS analysis, we identified 61 and 163 unique mutations in genomic regions potentially involved in BDQ- and DLM-resistant phenotypes, respectively. Importantly, all strains were isolated from patients who likely have never been exposed to the medicines. To characterize the role of mutations, we calculated the free energy variation upon mutations in the available protein structure of Ddn (DLM), Fgd1 (DLM) and Rv0678 (BDQ), and performed minimum inhibitory concentration (MIC) assays on a subset of MTBc strains carrying mutations to assess their phenotypic effect. The combination of structural and phenotypic data allowed for cataloging the mutations clearly associated with resistance to BDQ (n = 4) and DLM (n = 35) of which only two were previously described, as well as about a hundred genetic variants without any correlation with resistance. Significantly, these results show that both BDQ and DLM resistance-related mutations are diverse and distributed across the entire region of each gene target, which is of critical importance to the development of comprehensive molecular diagnostic tools.

6 December 2018 in African Journal of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
NINazir Ismail
Nazir Ismail
FIFarzana Ismail
Farzana Ismail
Shaheed Vally OmarShaheed Vally Omar
Shaheed Vally Omar
LBLinsay Blows
Linsay Blows
YGYasmin Gardee
Yasmin Gardee
POPhilip C. Onyebujoh
Philip C. Onyebujoh
The African Journal of Laboratory Medicine focuses on the role of the laboratory and its professionals in the clinical and public healthcare sectors, and is specifically based on an African frame of reference.

31 March 2023 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
EMEmily L. MacLean
Emily L. MacLean
PMPaolo Miotto
Paolo Miotto
LALice González Angulo
Lice González Angulo
MCMatteo Chiacchiaretta
Matteo Chiacchiaretta
TWTimothy M Walker
Timothy M Walker
MZMatteo Zignol
Matteo Zignol
There were approximately 10 million tuberculosis (TB) cases in 2020, of which 500,000 were drug-resistant. Only one third of drug-resistant TB cases were diagnosed and enrolled on appropriate treatment, an issue partly driven by a lack of rapid, accurate drug-susceptibility testing (DST) tools deployable in peripheral settings. In 2014, World Health Organization (WHO) published target product profiles (TPPs) which detailed minimal and optimal criteria to address high-priority TB diagnostic needs, including DST. Since then, the TB community’s needs have evolved; new treatment regimens, changes in TB definitions, further emergence of drug resistance, technological advances, and changing end-users requirements have necessitated an update. The DST TPP’s revision was therefore undertaken by WHO with the Stop TB Partnership New Diagnostics Working Group. We describe the process of updating the TPP for next-generation TB DST for use at peripheral centres, highlight key updates, and discuss guidance regarding technical and operational specifications.

25 May 2023 in BMJ Global Health
Verified
Journal Article
Open access
PDF file
NINazir Ismail
Nazir Ismail
CNCarl-Michael Nathanson
Carl-Michael Nathanson
MZMatteo Zignol
Matteo Zignol
TKTereza Kasaeva
Tereza Kasaeva